Home・Akcijų sąrašas・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

3.2 2.24

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.12

Max

3.25

Pagrindiniai rodikliai
By Trading Economics
Pajamos	4.1M -5.7M
Pelnas, tenkantis vienai akcijai	-0.06
Darbuotojai	34
EBITDA	-821K -6.5M

Dividendai
By Acuity
Kitas uždarbis	2026-08-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	42M 273M
Ankstesnė atidarymo kaina	0.96
Ankstesnė uždarymo kaina	3.2

Naujienos nuotaikos

By Acuity

50%

156 / 340 reitingas Healthcare

Anavex Life Sciences Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-05 21:01; UTC

Anavex Life Sciences shares fell in after-market trading, declining significantly despite being above its 20-day moving average and near the top of its one-month range.

2026-08-04 19:51; UTC

Anavex Life Sciences Corp is rising amid broader market strength and a decline in crude oil prices, despite pulling back from earlier session highs.

2026-08-03 20:02; UTC

News

Anavex Life Sciences Corp announces board changes amid a proxy fight, urging stockholders to reject PVG Asset Management's attempt to replace the board. Shares are higher.

2026-07-30 19:39; UTC

Event

Anavex Life Sciences reported Q2 earnings of -$0.06 per share, beating expectations. Shares remain higher since Wednesday's close despite pulling back from session highs.

2026-07-29 22:31; UTC

Anavex Life Sciences Corp shares are higher in after-market trading, reflecting broader market gains following the Federal Reserve's decision to maintain interest rates.

2026-07-28 21:01; UTC

Anavex Life Sciences Corp shares are lower in after-market hours, currently 1.45% below their 20-day moving average. No specific news was identified.

2026-07-27 20:07; UTC

Anavex Life Sciences Corp shares are higher during Monday's session, maintaining gains since Friday amid broader market trends and easing geopolitical tensions.

2026-07-24 17:46; UTC

Anavex Life Sciences Corp shares are lower today, continuing a decline since Thursday's close, with no specific news identified to explain the move.

2026-07-21 19:51; UTC

Anavex Life Sciences is rising during Tuesday's session, recovering from a pre-market low. Broader market sentiment is supported by positive earnings from General Motors and Novartis.

Akcijų palyginimas

Kainos pokytis

Anavex Life Sciences Corp Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių Anavex Life Sciences Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

156 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.